Lung Cancer | Specialty

Singh Discusses the Shift Toward Stereotactic Radiation Therapy in Lung Cancer

April 23rd 2024

Raj Singh, MD, discusses the use of stereotactic body radiation therapy and stereotactic radiosurgery in the treatment of patients with lung cancer.

Dr Eric Singhi Navigates Advocacy, Mentorship, and More in NSCLC Management

April 23rd 2024

Eric K. Singhe, MD, of The University of Texas MD Anderson Cancer Center, discusses the journey of non–smell cell lung cancer treatment through mentorship, advocacy, and more.

Tislelizumab Receives EU Approval in 3 Indications for First- and Second-Line NSCLC

April 23rd 2024

Tislelizumab has been approved in Europe across 3 indications in the first and second line for select patients with non–small cell lung cancer.

Health Canada Green Lights Subcutaneous Atezolizumab for Lung, Breast, and Liver Cancer

April 23rd 2024

Health Canada has approved subcutaneous atezolizumab for use in patients with lung cancer, breast cancer, and hepatocellular carcinoma.

FAK Inhibition Emerges as a Potential Complementary Treatment Pathway

April 22nd 2024

Although FAK inhibition alone has displayed modest activity to date, there is interest in developing FAK-targeted therapies for combination regimens.

Dr Saxena on Shifts in Treatment With Targeted and Immune Therapies in NSCLC

April 19th 2024

Ashish Saxena, MD, PhD, discusses recent shifts in treatment with the use of targeted and immune therapies in non–small cell lung cancer.

FDA Approves Adjuvant Alectinib for ALK+ Early-Stage NSCLC

April 18th 2024

The FDA has approved alectinib as adjuvant treatment in select patients with ALK-positive non–small cell lung cancer.

Biomarker Testing Challenges in HER2-mutated NSCLC

April 17th 2024

Experts on HER2-mutated non–small cell lung cancer provide clinical insights on biomarker testing challenges and the role of reflex testing.

Diagnosing HER2-mutated NSCLC

April 17th 2024

A panel of thoracic oncologists introduce themselves and discuss biomarker testing strategies and the diagnosis of HER2-mutated non–small cell lung cancer (NSCLC).

Dr Vallieres on the Role of Induction Therapy on Surgical Candidacy in Lung Cancer

April 16th 2024

Eric Vallieres, MD, FRCSC, discusses the impact of induction therapy on surgical candidacy and operative complexity in patients with thoracic malignancies.

Dr Levy on Multidisciplinary Treatment in Lung Cancer Care

April 15th 2024

Benjamin Levy, MD, discusses the utility of multidisciplinary treatment in lung cancer care.

March Approval Madness: OncLive’s Roundup of FDA Decisions in Oncology

April 13th 2024

In case you missed it, these were the key regulatory decisions made by the FDA in March 2024.

An Evolving Treatment Paradigm: ADCs in Non–Small Cell Lung Cancer

April 11th 2024

ON FEBRUARY 3, 2024, a select multidisciplinary group of physicians that included surgeons, radiation oncologists, and medical oncologists from academic and community practices participated in a live workshop to discuss current practices and recent updates on ADCs for the treatment of patients with NSCLC. A discussion moderated by Ticiana Leal, MD, provided perspectives and insights on approved and emerging ADCs in NSCLC including key clinical trial data on ADC efficacy and safety, treatment selection, and strategies to manage associated adverse events (AEs). Leal also presented patient cases for discussion.

Savolitinib/Osimertinib Yields Responses in EGFR-Mutant, MET-Amplified, Osimertinib-Resistant NSCLC

April 10th 2024

Responses with savolitinib plus osimertinib were higher in patients with NSCLC who had higher MET amplification cutoffs vs the overall population.

Dr Jänne on an Exploratory Analysis from FLAURA2 of Baseline ctDNA in EGFR+ NSCLC

April 10th 2024

FDA Grants Fast Track Designation to PT217 for Extensive Stage Small Cell Lung Cancer

April 9th 2024

The FDA has granted fast track designation to PT217 for patients with extensive stage small cell lung cancer with disease progression.

Datopotamab Deruxtecan (Dato-DXd) in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) – Nonsquamous (NSQ) Histology in the Phase 3 TROPION-Lung01 Trial

April 9th 2024

Jacob Sands, MD, shares updated data from the phase 3 TROPION-Lung01 trial of datopotamab deruxtecan versus docetaxel in non-squamous non-small cell lung cancer recently presented at the 2024 European Lung Cancer Congress (ELCC).

FDA Grants Breakthrough Therapy Designation to First-Line Sunvozertinib for EGFR Exon 20+ NSCLC

April 8th 2024

The FDA has granted breakthrough therapy designation to sunvozertinib for patients with locally advanced or metastatic NSCLC with an EGFR exon 20 insertion mutation.

Dr Chudgar on Defining Resectability in NSCLC

April 6th 2024

Neel P. Chudgar, MD, discusses his presentation on resectability in non–small cell lung cancer at the 21st Annual Winter Lung Cancer Conference®.

Dr Schneider on Treatment Considerations After Osimertinib in EGFR+ NSCLC

April 5th 2024

Jaime Schneider, MD, PhD, discusses considerations for patients with EGFR-mutant non–small cell lung cancer that progresses on osimertinib.